US EditionC-Path’s Translational Therapeutics Accelerator Announces New Grant Award for Drug Development Project in Type 1 Diabetes - Phoenix Bioscience Core
Summary by Phoenix Bioscience Core
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
C-Path’s Translational Therapeutics Accelerator Announces New Grant Award for Drug Development Project in Type 1 Diabetes - Phoenix Bioscience Core
Facebook Twitter LinkedIn Email Print TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment for type 1 diabetes (T1D). Kyle Apley, Ph.D., Cory Berkland, Ph.D., and Peggy Kendall M.D., at Washington University in St. Louis, have received this TRxA award to advance their work on a CD22 bidentate therapeuti…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
